Cutaneous Drug Reactions in the Pediatric Population

Pediatric Clinics of North America

Volumn 61, Issue 2, 2014, Pages 403-426

  Noguera Morel, Lucero ^a   Hernández Martín, Ángela ^a   Torrelo, Antonio ^a  

^a HOSPITAL INFANTIL UNIVERSITARIO NIÑO JESÚS   (Spain)

Author keywords

DRESS syndrome; Drug allergy; Exanthems; Hypersensitivity; Stevens Johnson syndrome; Toxic epidermal necrolysis; Urticaria

Indexed keywords

ALLOPURINOL; AMIODARONE; ANDROGEN; ANTIHISTAMINIC AGENT; ANTINEOPLASTIC AGENT; ARSENIC; CARBAMAZEPINE; CEFIXIME; CETUXIMAB; CLINDAMYCIN; CORTICOSTEROID; COTRIMOXAZOLE; ERLOTINIB; IMMUNOGLOBULIN E; IODINE DERIVATIVE; ISONIAZID; LAMOTRIGINE; LITHIUM; MACROLIDE; MINOCYCLINE; NONSTEROID ANTIINFLAMMATORY AGENT; OXCARBAZEPINE; OXICAM DERIVATIVE; PANITUMUMAB; PARACETAMOL; PENICILLIN DERIVATIVE; PHENYTOIN; SULFAMETHOXAZOLE; UNINDEXED DRUG; VANCOMYCIN;

ACNE; ACUTE GENERALIZED EXANTHEMATOUS PUSTULOSIS; ADVERSE DRUG REACTION; ALOPECIA; CLINICAL FEATURE; CUTANEOUS ADVERSE DRUG REACTION; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DISEASE SEVERITY; DRESS SYNDROME; DRUG ERUPTION; DRUG HYPERSENSITIVITY; EOSINOPHILIA; FEVER; FIXED DRUG ERUPTION; HISTOPATHOLOGY; HUMAN; IMMUNOPATHOGENESIS; LABORATORY TEST; MACULOPAPULAR RASH; MUCOSA INFLAMMATION; PAIN; PALMOPLANTAR KERATODERMA; PATHOPHYSIOLOGY; PLASMAPHERESIS; PRACTICE GUIDELINE; PROGNOSIS; PRURITUS; REVIEW; SERUM SICKNESS; SERUM SICKNESS LIKE REACTION; SKIN BIOPSY; SKIN DISCOLORATION; SKIN DISEASE; SKIN NECROSIS; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; STEVENS JOHNSON SYNDROME; SYMPTOM; TOXIC EPIDERMAL NECROSIS; URTICARIA; VESICULOBULLOUS ERUPTION;

DRESS SYNDROME; DRUG ALLERGY; EXANTHEMS; HYPERSENSITIVITY; STEVENS-JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS; URTICARIA;

CHILD; DIAGNOSIS, DIFFERENTIAL; DRUG ERUPTIONS; DRUG HYPERSENSITIVITY; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS;

EID: 84897647938     PISSN: 00313955     EISSN: 15578240     Source Type: Journal    
DOI: 10.1016/j.pcl.2013.12.001     Document Type: Review

References (75)

1. Koren G. Protecting young children from life-threatening drug toxicity. JPediatr 2013, 163(5):1249-1250. Available at:, Accessed August 11, 2013. http://www.ncbi.nlm.nih.gov/pubmed/23809045.
2. WHO Media centre. Medicines: safety of medicines-adverse drug reactions. Fact sheet. 2008 (October).
3. Ott H. Hypersensitivity reactions to drugs. Harper's textbook of pediatric dermatology 2011, 2816. Blackwell Publishing Ltd. 3rd edition. A.D. Irvine, P.H. Hoeger, A.C. Yan (Eds.).
4. Posadas S.J., Pichler W.J. Delayed drug hypersensitivity reactions-new concepts. Clin Exp Allergy 2007, 37(7):989-999. Available at:, Accessed August 11, 2013. http://www.ncbi.nlm.nih.gov/pubmed/17581192.
5. Pichler W.J., Adam J., Daubner B., et al. Drug hypersensitivity reactions: pathomechanism and clinical symptoms. Med Clin North Am 2010, 94(4):645-664. xv. Available at:, Accessed August 11, 2013. http://www.ncbi.nlm.nih.gov/pubmed/20609855.
6. Heelan K., Shear N.H. Cutaneous drug reactions in children: an update. Paediatr Drugs 2013, 15(6):493-503. Available at:, Accessed August 11, 2013. http://www.ncbi.nlm.nih.gov/pubmed/23842849.
7. Coombs P., Gell P. Classification of allergic reactions responsible for clinical hypersensitivity and disease. Clinical aspects of immunology 1968, 575-596. Oxford University Press, Oxford (United kingdom). P. Gell (Ed.).
8. Lerch M., Pichler W.J. The immunological and clinical spectrum of delayed drug-induced exanthems. Curr Opin Allergy Clin Immunol 2004, 4(5):411-419. Available at:. http://www.ncbi.nlm.nih.gov/pubmed/15349041.
9. Lee H.Y., Chung W.H. Toxic epidermal necrolysis: the year in review. Curr Opin Allergy Clin Immunol 2013, 13(4):330-336. Available at:, Accessed August 11, 2013. http://www.ncbi.nlm.nih.gov/pubmed/23799330.
10. Yawalkar N. Drug-induced exanthems. Toxicology 2005, 209(2):131-134. Available at:, Accessed November 1, 2013. http://www.ncbi.nlm.nih.gov/pubmed/15767025.
11. Khaled A., Kharfi M., Ben Hamida M., et al. Cutaneous adverse drug reactions in children. A series of 90 cases. Tunis Med 2012, 90(1):45-50. Available at:, Accessed August 25, 2013. http://www.ncbi.nlm.nih.gov/pubmed/22311448.
12. Pirmohamed M. Genetics and the potential for predictive tests in adverse drug reactions. Chem Immunol Allergy 2012, 97:18-31.
13. Mockenhaupt M. Epidemiology of cutaneous adverse drug reactions. Chem Immunol Allergy 2012, 97:1-17. Available at:, Accessed August 24, 2013. http://www.ncbi.nlm.nih.gov/pubmed/22613850.
14. Menniti-Ippolito G., Raschetti R., Da Cas R., et al. Active monitoring of adverse drug reactions in children. Italian Paediatric Pharmacosurveillance Multicenter Group. Lancet 2000, 355(9215):1613-1614. Available at:, Accessed August 24, 2013. http://www.ncbi.nlm.nih.gov/pubmed/10821367.
15. Rebelo Gomes E., Fonseca J., Araujo L., et al. Drug allergy claims in children: from self-reporting to confirmed diagnosis. Clin Exp Allergy 2008, 38(1):191-198. Available at:, Accessed August 24, 2013. http://www.ncbi.nlm.nih.gov/pubmed/18028465.
16. Harr T., French L.E. Toxic epidermal necrolysis and Stevens-Johnson syndrome. Orphanet J Rare Dis 2010, 5:39. Available at:, Accessed August 24, 2013. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3018455%26tool=pmcentrez%26rendertype=abstract.
17. Mockenhaupt M. Severe drug-induced skin reactions: clinical pattern, diagnostics and therapy. JDtsch Dermatol Ges 2009, 7(2):142-160. [quiz: 161-2]. Available at:, Accessed October 11, 2013. http://www.ncbi.nlm.nih.gov/pubmed/19371237.
18. Peroni A., Colato C., Schena D., et al. Urticarial lesions: if not urticaria, what else? The differential diagnosis of urticaria: part I. Cutaneous diseases. JAm Acad Dermatol 2010, 62(4):541-555. [quiz: 555-6]. Available at:, Accessed October 7, 2012. http://www.ncbi.nlm.nih.gov/pubmed/20227576.
19. Bigby M. Rates of cutaneous reactions to drugs. Arch Dermatol 2001, 137(6):765-770. Available at:. http://www.ncbi.nlm.nih.gov/pubmed/11444258.
20. Díaz Jara M., Pérez Montero A., Gracia Bara M.T., et al. Allergic reactions due to ibuprofen in children. Pediatr Dermatol 2001, 18(1):66-67. Available at:. http://www.ncbi.nlm.nih.gov/pubmed/11207978.
21. Tamayo-Sanchez L., Ruiz-Maldonado R., Laterza A. Acute annular urticaria in infants and children. Pediatr Dermatol 1997, 14(3):231-234. Available at:. http://www.ncbi.nlm.nih.gov/pubmed/9192421.
22. Peroni A., Colato C., Zanoni G., et al. Urticarial lesions: if not urticaria, what else? The differential diagnosis of urticaria: part II. Systemic diseases. JAm Acad Dermatol 2010, 62(4):557-570. [quiz: 571-2]. Available at:, Accessed October 7, 2012. http://www.ncbi.nlm.nih.gov/pubmed/20227577.
23. Paller A.S., Mancini A.J. Allergic reactions. Hurwitz clinical pediatric dermatology 2011, 454-482. Elsevier Saunders, Philadelphia, Available at:, Accessed August 11, 2013. http://www.expertconsult.com, 4th edition. A.S. Paller, A.J. Mancini (Eds.).
24. Ibia E.O., Schwartz R.H., Wiedermann B.L. Antibiotic rashes in children. Arch Dermatol 2000, 136:849-854.
25. Ribeiro-Vaz I., Marques J., Demoly P., et al. Drug-induced anaphylaxis: a decade review of reporting to the Portuguese Pharmacovigilance Authority. Eur J Clin Pharmacol 2013, 69(3):673-681. Available at:, Accessed September 28, 2013. http://www.ncbi.nlm.nih.gov/pubmed/22915040.
26. Erlewyn-Lajeunesse M., Hunt L.P., Heath P.T., et al. Anaphylaxis as an adverse event following immunisation in the UK and Ireland. Arch Dis Child 2012, 97(6):487-490. Available at:, Accessed September 28, 2013. http://www.ncbi.nlm.nih.gov/pubmed/22275307.
27. Tolpinrud W.L., Bunick C.G., King B.A. Serum sickness-like reaction: histopathology and case report. JAm Acad Dermatol 2011, 65(3):e83-e85. Available at:, Accessed September 8, 2013. http://www.ncbi.nlm.nih.gov/pubmed/21839305.
28. Patel S., Mancini A.J. Serum sickness-like reaction in children: a retrospective review. JAm Acad Dermatol 2009, 60(Suppl 1):AB1-AB276.
29. Emer J.J., Bernardo S.G., Kovalerchik O., et al. Urticaria multiforme. JClin Aesthet Dermatol 2013, 6(3):34-39. Available at:. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3613272%26tool=pmcentrez%26rendertype=abstract.
30. Bircher A.J. Uncomplicated drug-induced disseminated exanthemas. Chem Immunol Allergy 2012, 97:79-97. Available at:. http://www.ncbi.nlm.nih.gov/pubmed/22613855.
31. Chovel-Sella A., Ben Tov A., Lahav E., et al. Incidence of rash after amoxicillin treatment in children with infectious mononucleosis. Pediatrics 2013, 131(5):e1424-e1427. Available at:, Accessed September 29, 2013. http://www.ncbi.nlm.nih.gov/pubmed/23589810.
32. Segal A.R., Doherty K.M., Leggott J., et al. Cutaneous reactions to drugs in children. Pediatrics 2007, 120(4):e1082-e1096. Available at:, Accessed August 15, 2013. http://www.ncbi.nlm.nih.gov/pubmed/17908729.
33. Husain Z., Reddy B.Y., Schwartz R.A. DRESS syndrome: part I. Clinical perspectives. JAm Acad Dermatol 2013, 68(5):693.e1-693.e14. [quiz: 706-8]. Available at:, Accessed August 8, 2013. http://www.ncbi.nlm.nih.gov/pubmed/23602182.
34. Ferrero N.A., Pearson K.C., Zedek D.C., et al. Case report of drug rash with eosinophilia and systemic symptoms demonstrating human herpesvirus-6 reactivation. Pediatr Dermatol 2013, 30(5):608-613. Available at:, Accessed October 19, 2013. http://www.ncbi.nlm.nih.gov/pubmed/24016284.
35. Pavlos R., Mallal S., Phillips E. HLA and pharmacogenetics of drug hypersensitivity. Pharmacogenomics 2012, 13(11):1285-1306. Available at:, Accessed August 24, 2013. http://www.ncbi.nlm.nih.gov/pubmed/22920398.
36. Kardaun S.H., Sekula P., Valeyrie-Allanore L., et al. Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study. Br J Dermatol 2013, 169(5):1071-1080. Available at:, Accessed August 24, 2013. http://www.ncbi.nlm.nih.gov/pubmed/23855313.
37. Chiou C.C., Yang L.C., Hung S.I., et al. Clinicopathological features and prognosis of drug rash with eosinophilia and systemic symptoms: a study of 30 cases in Taiwan. JEur Acad Dermatol Venereol 2008, 22(9):1044-1049. Available at:, Accessed August 3, 2013. http://www.ncbi.nlm.nih.gov/pubmed/18627428.
38. Cacoub P., Musette P., Descamps V., et al. The DRESS syndrome: a literature review. Am J Med 2011, 124(7):588-597. Available at:, Accessed August 3, 2013. http://www.ncbi.nlm.nih.gov/pubmed/21592453.
39. Tohyama M., Hashimoto K. New aspects of drug-induced hypersensitivity syndrome. JDermatol 2011, 38(3):222-228. Available at:, Accessed August 3, 2013. http://www.ncbi.nlm.nih.gov/pubmed/21342223.
40. Levi N., Bastuji-Garin S., Mockenhaupt M., et al. Medications as risk factors of Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a pooled analysis. Pediatrics 2009, 123(2):e297-e304.
41. Chung W.H., Hung S.I. Recent advances in the genetics and immunology of Stevens-Johnson syndrome and toxic epidermal necrosis. JDermatol Sci 2012, 66(3):190-196. Available at:, Accessed August 24, 2013. http://www.ncbi.nlm.nih.gov/pubmed/22541332.
42. Yip V.L., Marson A.G., Jorgensen A.L., et al. HLA genotype and carbamazepine-induced cutaneous adverse drug reactions: a systematic review. Clin Pharmacol Ther 2012, 92(6):757-765. Available at:, Accessed September 17, 2013. http://www.ncbi.nlm.nih.gov/pubmed/23132554.
43. Guégan S., Bastuji-Garin S., Poszepczynska-Guigné E., et al. Performance of the SCORTEN during the first five days of hospitalization to predict the prognosis of epidermal necrolysis. JInvest Dermatol 2006, 126(2):272-276. Available at:, Accessed October 19, 2013. http://www.ncbi.nlm.nih.gov/pubmed/16374461.
44. Palmieri T.L., Greenhalgh D.G., Saffle J.R., et al. Amulticenter review of toxic epidermal necrolysis treated in U.S. burn centers at the end of the twentieth century. JBurn Care Rehabil 2002, 23(2):87-96. Available at:, Accessed November 5, 2013. http://www.ncbi.nlm.nih.gov/pubmed/11882797.
45. Huang S.H., Yang P.S., Wu S.H., et al. Aquacel Ag with Vaseline gauze in the management of toxic epidermal necrolysis (TEN). Burns 2010, 36(1):121-126. Available at:, Accessed November 5, 2013. http://www.ncbi.nlm.nih.gov/pubmed/19477595.
46. Boorboor P., Vogt P.M., Bechara F.G., et al. Toxic epidermal necrolysis: use of Biobrane or skin coverage reduces pain, improves mobilisation and decreases infection in elderly patients. Burns 2008, 34(4):487-492. Available at:, Accessed November 5, 2013. http://www.ncbi.nlm.nih.gov/pubmed/17919820.
47. Dorafshar A.H., Dickie S.R., Cohn A.B., et al. Antishear therapy for toxic epidermal necrolysis: an alternative treatment approach. Plast Reconstr Surg 2008, 122(1):154-160. Available at:, Accessed November 5, 2013. http://www.ncbi.nlm.nih.gov/pubmed/18594400.
48. Yip L.W., Thong B.Y., Lim J., et al. Ocular manifestations and complications of Stevens-Johnson syndrome and toxic epidermal necrolysis: an Asian series. Allergy 2007, 62(5):527-531. Available at:, Accessed October 3, 2013. http://www.ncbi.nlm.nih.gov/pubmed/17313402.
49. Ersoy S., Paller A.S., Mancini A.J. Acute generalized exanthematous pustulosis in children. Arch Dermatol 2004, 140(9):1172-1173.
50. Meadows K.P., Egan C.A., Vanderhooft S. Acute generalized exanthematous pustulosis (AGEP), an uncommon condition in children: case report and review ofthe literature. Pediatr Dermatol 2000, 17(5):399-402. Available at:, Accessed August 25, 2013. http://doi.wiley.com/10.1046/j.1525-1470.2000.017005399.x.
51. Lansang P., Weinstein M., Shear N. Drug reactions. Pediatric dermatology 2011, 1698-1711. Mosby Elsevier, London. 4th edition. L.A. Schachner, R.C. Hansen (Eds.).
52. Fathallah N., Ben Salem C., Slim R., et al. Acetaminophen-induced cellulitis-like fixed drug eruption. Indian J Dermatol 2011, 56(2):206-208. Available at:, Accessed August 26, 2013. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3108524%26tool=pmcentrez%26rendertype=abstract.
53. Nussinovitch M., Prais D., Ben-Amitai D., et al. Fixed drug eruption in the genital area in 15 boys. Pediatr Dermatol 2002, 19(3):216-219. Available at:. http://www.ncbi.nlm.nih.gov/pubmed/12047640.
54. Bilgili S.G., Calka O., Karadag A.S., et al. Nonsteroidal anti-inflammatory drugs-induced generalized fixed drug eruption: two cases. Hum Exp Toxicol 2012, 31(2):197-200. Available at:, Accessed August 26, 2013. http://www.ncbi.nlm.nih.gov/pubmed/21677025.
55. Mahboob A., Haroon T.S. Drugs causing fixed eruptions: a study of 450 cases. Int J Dermatol 1998, 37(11):833-838. Available at:, Accessed November 5, 2013. http://www.ncbi.nlm.nih.gov/pubmed/9865869.
56. Brahimi N., Routier E., Raison-Peyron N., et al. Athree-year-analysis of fixed drug eruptions in hospital settings in France. Eur J Dermatol 2010, 20(4):461-464. Available at:, Accessed November 5, 2013. http://www.ncbi.nlm.nih.gov/pubmed/20507840.
57. Paller A.S., Mancini A.J. Hurwitz clinical pediatric dermatology: a textbook of skin disorders of childhood and adolescence 2011, 624. Elsevier Inc, Philadelphia, Available at:, Accessed August 11, 2013. http://www.expertconsult.com, 4th edition. A.S. Paller, A.J. Mancini (Eds.).
58. Revuz J., Valeyrie-Allanore L. Drug reactions in dermatology. Dermatology 2012, Cp21. Elsevier Inc, Philadelphia. 3rd edition. L. Jean, M. Bolognia, V. Julie (Eds.).
59. Wolverton S.E. Comprehensive dermatologic drug therapy 2013, Elsevier Saunders, Philadelphia. 3rd edition.
60. Gatti L., Carnelli V., Rusconi R., et al. Heparin-induced thrombocytopenia and warfarin-induced skin necrosis in a child with severe protein C deficiency: successful treatment with dermatan sulfate and protein C concentrate. JThromb Haemost 2003, 1(2):387-388. Available at:, Accessed November 7, 2013. http://www.ncbi.nlm.nih.gov/pubmed/12871519.
61. Warkentin T.E. Heparin-induced skin lesions. Br J Haematol 1996, 92(2):494-497. Available at:, Accessed November 7, 2013. http://www.ncbi.nlm.nih.gov/pubmed/8603024.
62. Ho J.C., Ng P.L., Tan S.H., et al. Childhood linear IgA bullous disease triggered by amoxicillin-clavulanic acid. Pediatr Dermatol 2007, 24(5):E40-E43. Available at:, Accessed November 7, 2013. http://www.ncbi.nlm.nih.gov/pubmed/17958778.
63. Mintz E.M., Morel K.D. Clinical features, diagnosis, and pathogenesis of chronic bullous disease of childhood. Dermatol Clin 2011, 29(3):459-462. ix. Available at:, Accessed November 7, 2013. http://www.ncbi.nlm.nih.gov/pubmed/21605812.
64. Cardoza-Torres M.A., Liy-Wong C., Welsh O., et al. Skin manifestations associated with chemotherapy in children with hematologic malignancies. Pediatr Dermatol 2012, 29(3):264-269. Available at:, Accessed August 12, 2013. http://www.ncbi.nlm.nih.gov/pubmed/22044286.
65. Heinzerling L.M., Tomsitz D., Anliker M.D. Is drug allergy less prevalent than previously assumed? A 5-year analysis. Br J Dermatol 2012, 166(1):107-114. Available at:, Accessed August 25, 2013. http://www.ncbi.nlm.nih.gov/pubmed/21916887.
66. Guillon J.M., Joly P., Autran B., et al. Minocycline-induced cell-mediated hypersensitivity pneumonitis. Ann Intern Med 1992, 117(6):476-481. Available at:, Accessed November 5, 2013. http://www.ncbi.nlm.nih.gov/pubmed/1503350.
67. Stern R.S. Clinical practice. Exanthematous drug eruptions. NEngl J Med 2012, 366(26):2492-2501. Available at:, Accessed November 5, 2013. http://www.ncbi.nlm.nih.gov/pubmed/22738099.
68. Kano Y., Hirahara K., Mitsuyama Y., et al. Utility of the lymphocyte transformation test in the diagnosis of drug sensitivity: dependence on its timing and the type of drug eruption. Allergy 2007, 62(12):1439-1444. Available at:, Accessed November 5, 2013. http://www.ncbi.nlm.nih.gov/pubmed/17983378.
69. Amur S., Frueh F.W., Lesko L.J., et al. Integration and use of biomarkers in drug development, regulation and clinical practice: a US regulatory perspective. Biomark Med 2008, 2(3):305-311. Available at:. http://www.ncbi.nlm.nih.gov/pubmed/20477416.
70. Husain Z., Reddy B.Y., Schwartz R.A. DRESS syndrome: part II. Management and therapeutics. JAm Acad Dermatol 2013, 68(5):709.e1-709.e9. [quiz: 718-20]. Available at:, Accessed August 8, 2013. http://www.ncbi.nlm.nih.gov/pubmed/23602183.
71. Laban E., Hainaut-Wierzbicka E., Pourreau F., et al. Cyclophosphamide therapy for corticoresistant drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome in a patient with severe kidney and eye involvement and Epstein-Barr virus reactivation. Am J Kidney Dis 2010, 55(3):e11-e14. Available at:, Accessed July 31, 2012. http://www.ncbi.nlm.nih.gov/pubmed/20110143.
72. Zuliani E., Zwahlen H., Gilliet F., et al. Vancomycin-induced hypersensitivity reaction with acute renal failure: resolution following cyclosporine treatment. Clin Nephrol 2005, 64(2):155-158. Available at:. http://www.ncbi.nlm.nih.gov/pubmed/16114793.
73. Reese D., Henning J.S., Rockers K., et al. Cyclosporine for SJS/TEN: a case series and review of the literature. Cutis 2011, 87:24-29.
74. Schneck J., Fagot J.P., Sekula P., et al. Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: a retrospective study on patients included in the prospective EuroSCAR Study. JAm Acad Dermatol 2008, 58(1):33-40. Available at:, Accessed September 20, 2013. http://www.ncbi.nlm.nih.gov/pubmed/17919775.
75. Valeyrie-Allanore L., Wolkenstein P., Brochard L., et al. Open trial of cyclosporin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis. Br J Dermatol 2010, 163(4):847-853. Available at:, Accessed July 31, 2012. http://www.ncbi.nlm.nih.gov/pubmed/20500799.